PharmaCyte Biotech Inc. (PMCB): Price and Financial Metrics


PharmaCyte Biotech Inc. (PMCB): $2.23

0.04 (+1.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PMCB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PMCB Stock Price Chart Interactive Chart >

Price chart for PMCB

PMCB Price/Volume Stats

Current price $2.23 52-week high $21.45
Prev. close $2.19 52-week low $1.79
Day low $2.19 Volume 44,000
Day high $2.26 Avg. volume 335,374
50-day MA $2.23 Dividend yield N/A
200-day MA $2.62 Market Cap 46.21M

PharmaCyte Biotech Inc. (PMCB) Company Bio


PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.


PMCB Latest News Stream


Event/Time News Detail
Loading, please wait...

PMCB Latest Social Stream


Loading social stream, please wait...

View Full PMCB Social Stream

Latest PMCB News From Around the Web

Below are the latest news stories about PharmaCyte Biotech Inc that investors may wish to consider to help them evaluate PMCB as an investment opportunity.

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

LAS VEGAS, February 22, 2022--PharmaCyte announces genetic stability of the cytochrome P450 gene and site of integration for its pancreatic cancer product candidate.

Yahoo | February 22, 2022

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

LAS VEGAS, February 14, 2022--PharmaCyte Biotech updates status of its Investigational New Drug Application to the FDA.

Yahoo | February 14, 2022

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

LAS VEGAS, January 06, 2022--PharmaCyte Biotech Chief Executive Officer to present at the H.C. Wainwright BioConnect Conference.

Yahoo | January 6, 2022

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

LAS VEGAS, January 04, 2022--PharmaCyte Biotech biocompatibility study proves that its capsule material is not toxic for the encapsulated cells inside the capsules.

Yahoo | January 4, 2022

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

LAS VEGAS, December 28, 2021--PharmaCyte has successfully completed a 36 month stability study on its Master Cell Bank cells that will be used for treatment of pancreatic cancer.

Yahoo | December 28, 2021

Read More 'PMCB' Stories Here

PMCB Price Returns

1-mo -4.29%
3-mo 4.69%
6-mo -13.90%
1-year -88.29%
3-year -96.15%
5-year -97.90%
YTD -10.80%
2021 -75.12%
2020 -83.46%
2019 9.46%
2018 -33.69%
2017 -62.53%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5718 seconds.